MERCK SHARP & DOHME CORP

Their core work

Merck Sharp & Dohme (known as MSD outside the US) is a global pharmaceutical company that brings deep drug development and safety expertise to European research consortia. In H2020, they contributed industry-side knowledge in drug safety assessment, translational biomarkers, vaccine immunology, and patient-centered regulatory science. Their participation spans the full drug lifecycle — from preclinical toxicology and imaging biomarker validation to patient preference studies and post-market environmental impact of pharmaceuticals. As a major pharma partner, they provide real-world clinical data, proprietary compound libraries, and regulatory experience that academic-only consortia typically lack.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), MSD focused on regulatory science and adaptive drug development pathways (ADAPT-SMART), Ebola vaccine clinical trials (VSV-EBOPLUS), and patient preference research (PREFER). From 2019 onward, their portfolio shifted decisively toward preclinical drug safety — toxicology prediction, safety biomarkers, immune system modeling, and neurotoxicity de-risking became dominant themes. The latest projects (2020+) extend into environmental impact of pharmaceuticals and digital supply chain integrity, suggesting MSD is broadening from internal drug safety to the full societal footprint of its products.

MSD is investing heavily in predictive safety science and environmental pharmacology — future partners should expect interest in computational toxicology, organ-on-chip models, and green chemistry for drug design.

How they like to work

MSD participates exclusively as a consortium partner, never as coordinator — consistent with large pharma's typical role of contributing industry data, compounds, and regulatory expertise while letting academic or public-sector partners lead. With 212 unique partners across 25 countries, they operate as a broad-network collaborator rather than a repeat-partner hub. Their involvement in IMI2 (Innovative Medicines Initiative) projects signals comfort with large, multi-party public-private partnerships where pharma companies share pre-competitive data.

MSD has collaborated with 212 unique partners across 25 countries, forming one of the wider pharmaceutical industry networks in H2020. Their reach spans Europe broadly, with additional connections through their US headquarters and global clinical trial infrastructure.

What sets them apart

MSD brings something few academic partners can: real pharmaceutical compounds, proprietary safety databases, and direct experience navigating regulatory approval processes across major markets. Their consistent focus on drug safety across multiple modalities (imaging, biomarkers, computational models, organ-on-chip) makes them one of the most committed pharma contributors to pre-competitive safety science in H2020. For consortium builders, MSD offers industry validation and access to clinical-grade data that strengthens any grant application in translational medicine or regulatory science.

Highlights from their portfolio

• imSAVAR
  Combines computational immunology with micro-physiological systems (organ-on-chip) to predict immune safety of new therapies — at the frontier of replacing animal testing.
• PREMIER
  Extends pharma responsibility into environmental risk assessment and greener drug design — an unusual and forward-looking direction for a major pharmaceutical company.
• VSV-EBOPLUS
  Applied systems vaccinology to analyze adult and pediatric responses to the VSV-ZEBOV Ebola vaccine during a global health emergency, running from 2016 to 2023.